1,667 reports of this reaction
3.9% of all Praluent reports
#1 most reported adverse reaction
MYALGIA is the #1 most commonly reported adverse reaction for Praluent, manufactured by Regeneron Pharmaceuticals, Inc.. There are 1,667 FDA adverse event reports linking Praluent to MYALGIA. This represents approximately 3.9% of all 42,517 adverse event reports for this drug.
Patients taking Praluent who experience myalgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYALGIA is moderately reported among Praluent users, representing a notable but not dominant share of adverse events.
In addition to myalgia, the following adverse reactions have been reported for Praluent:
The following drugs have also been linked to myalgia in FDA adverse event reports:
MYALGIA has been reported as an adverse event in 1,667 FDA reports for Praluent. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYALGIA accounts for approximately 3.9% of all adverse event reports for Praluent, making it one of the most commonly reported side effect.
If you experience myalgia while taking Praluent, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.